Ryvu Therapeutics (WAR:RVU) Total Equity: zł41.33 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:RVU Ryvu Therapeutics SA WAR:RVU
66 GF Score
Price zł14.98
GF Value zł45.84
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Total Equity?

Ryvu Therapeutics WAR:RVU -2.09% 66 Total Equity is zł41.33 Mil as of Mar. 2026. GuruFocus rates WAR:RVU with a GF Score™ of 66/100 and a GF Value™ of zł45.84 (Possible Value Trap). The stock has 3 warning signs investors should review.

Ryvu Therapeutics's total equity for the quarter that ended in Mar. 2026 was zł41.33 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Ryvu Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics Total Equity Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161.30 343.39 259.59 152.29 53.83

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.60 95.24 71.22 53.83 41.33
WAR:RVU
66GF Score
Ryvu Therapeutics SA WAR:RVU
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Ryvu Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=224.436-170.602
=53.83

Ryvu Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=200.955-159.629
=41.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of zł41.33 Mil mean?
Ryvu Therapeutics (WAR:RVU) has a Total Equity of zł41.33 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' Total Equity too high?
Ryvu Therapeutics' current Total Equity is zł41.33 Mil. Overall, Ryvu Therapeutics has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Total Equity compare to VRTX and REGN?
Ryvu Therapeutics' Total Equity of zł41.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current Total Equity is zł41.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (WAR:RVU) is currently considered Possible Value Trap. The stock's GF Value™ is zł45.84, compared to a current price of zł14.98 — trading 67.3% below its estimated fair value. The current Total Equity is zł41.33 Mil. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Ryvu Therapeutics (WAR:RVU), the current Total Equity is zł41.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (WAR:RVU) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł14.98 is trading 67.3% below its estimated GF Value™ of zł45.84. GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.

Key valuation signals for WAR:RVU:

  • Total Equity: zł41.33 Mil
  • GF Value™: zł45.84 vs. price of zł14.98 (67.3% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the WAR:RVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges 9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for WAR:RVU

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł14.98
Price
zł45.84
GF Value